Results 181 to 190 of about 99,760 (276)

FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome. [PDF]

J Clin Invest
Niederkorn M, Bezavada L, Cotton A, Palmer LE, Konada L, Hall T, Pagala VR, Zhai J, Yuan ZF, Fu Y, Steele JA, Narina S, Schild A, Wu C, Aminov S, Schieber M, McGovern E, Taylor AB, Gurbuxani S, Xu P, Ji P, Janke LJ, High AA, Kang G, Pruett-Miller SM, Weiss M, Verma A, Rampal RK, Crispino JD.   +28 more
europepmc   +1 more source

Incidence patterns and temporal trends of childhood cancer in Germany, 1980–2019: Forty years of childhood cancer registration in Germany

International Journal of Cancer, Volume 158, Issue 6, Page 1541-1554, 15 March 2026.
What's new? Childhood cancer ranks among the leading causes of disease‐related deaths in children in high‐income countries. Established risk factors, however, account for only a small proportion of incident childhood cancers. In this report, the authors present the first long‐term assessment of temporal trends in childhood cancer incidence rates in ...
Friederike Erdmann, Maike Wellbrock, Claudia Trübenbach, Desiree Grabow, Martin Schrappe, Peter Kaatsch, Claudia Spix, Joachim Schüz, Cécile M. Ronckers   +8 more
wiley   +1 more source

Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia. [PDF]

Cancers (Basel)
Hunter CJ, Im AP, Shallis RM.
europepmc   +1 more source

Improved survival after acute graft-versus-host disease diagnosis in the modern era [PDF]

, 2017
et al.,, Hayashi, Robert J, Vig, Ravi
core   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

Atypical orbital mass as the precursor for myelodysplastic syndrome recurrence: a case report. [PDF]

Am J Ophthalmol Case Rep
Demas N, Hernandez J, Timoney P.
europepmc   +1 more source

Severe Hidradenitis Suppurativa and Subsequent Myelodysplastic Syndrome: A Case Report Highlighting Chronic Inflammatory Burden and Carcinogenic Risk. [PDF]

Cureus
Rosas García MR, Maldonado-Colin G, Achell Nava L, Barajas BD, Alanis R.   +4 more
europepmc   +1 more source

Effect of RAS Pathway Gene Mutations on Survival in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. [PDF]

Cancer Control
Eslalakawi Y, Saad MO, Sanosi AS, Mesilhy R, Al-Mashdali AF, Omar NE, Saleh AO, Abdalla E, Elfatih A, Mohamed SF.   +9 more
europepmc   +1 more source

Clinical Characteristics and Molecular Profiling of <i>SF3B1</i>-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice. [PDF]

Int J Mol Sci
Wang RR, Than H, Tham C, How GF, Khoo SJ, Tuy TT.   +5 more
europepmc   +1 more source

Febrile Neutropenia in the Context of Clozapine-Induced Agranulocytosis (CIA) and Myelodysplastic Syndrome: Importance of a Multidisciplinary Approach. [PDF]

Cureus
Conchinha AF, Pack T, Rodrigues A, Lopes A, Santos A.   +4 more
europepmc   +1 more source